Cardiometabolic effects of antidiabetic drugs in non‐alcoholic fatty liver disease

Rix, Iben; Pedersen, Julie Steen; Storgaard, Heidi; Gluud, Lise Lotte

doi:10.1111/cpf.12526

Cited by 4 publications

(2 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antidiabetic drugs that increase insulin sensitivity are associated with a reduced risk of CVD and may have beneficial effects in the progression of NAFLD. [ 42 ] The effects of thiazolidinediones on advanced liver fibrosis were studied in a meta-analysis (eight RCTs; n=516). [ 43 ] Pioglitazone was associated with improved advanced fibrosis (OR 3.15; 95% CI [1.25–7.93]; p=0.01; I[ 2 ]=0%), fibrosis of any stage (OR 1.66; 95% CI [1.12–2.47]; p=0.01; I[ 2 ]=0%) and NASH resolution (OR 3.22; 95% CI [2.17–4.79]; p<0.001; I[ 2 ]=0%).…”

Section: Management Of Non-alcoholic Fatty Liver Diseasementioning

confidence: 99%

“…Antidiabetic drugs that increase insulin sensitivity are associated with a reduced risk of CVD and may have beneficial effects in the progression of NAFLD. 42 The effects of thiazolidinediones on advanced liver fibrosis were studied in a meta-analysis (eight RCTs; n=516). 43 43 However, weight gain and lower limb oedema occurred more frequently with thiazolidinedione therapy (initial body weight+2.70%; 95% CI [1.96-4.34%]; p=0.001).…”

Section: Pharmacological Managementmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Management of Non-alcoholic Steatohepatitis and the Role of the Cardiologist

Millán-Rodríguez,

Palacios Castelló,

Caballero-Valderrama

et al. 2023

Eur Cardiol

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of fat-associated liver conditions that increase risk of cardiovascular disease and mortality. The diagnosis and clinical management of NAFLD remain a challenge for cardiologists. Our group performed a systematic review in PubMed of the relationship between NAFLD and cardiovascular disease, identifying 35 relevant articles. NAFLD is likely to be the liver’s expression of metabolic syndrome and increases the risk of several cardiovascular diseases, including coronary artery disease, stroke, heart failure and electrical disorders, and chronic kidney disease. Echocardiography is a useful tool to check early subclinical abnormalities in heart structure and function linked to NAFLD progression, such as cardiac diastolic impairment or epicardial fat thickness. Currently, NAFLD is predominantly managed by lifestyle changes with the aim of weight loss, based on the Mediterranean diet and intense exercise training. Despite the lack of approved drugs for NAFLD, new potential treatments, mainly glucagon-like peptide-1 agonists or sodium–glucose cotransporter 2 inhibitors, could change cardiologists’ approach to this pathology.

show abstract

Section: Management Of Non-alcoholic Fatty Liver Diseasementioning

confidence: 99%